<DOC>
	<DOCNO>NCT02277704</DOCNO>
	<brief_summary>This 12-week , multicenter , randomize , double-blind , placebo-controlled , fixed-dose , parallel-group study investigate efficacy safety two dose TNX-102 SL â€”a sublingual formulation cyclobenzaprine . Following successful screen randomization , eligible subject return regularly study clinic weekly biweekly visit assessment efficacy safety .</brief_summary>
	<brief_title>Safety Efficacy Study TNX-102 SL Subjects With Military-Related PTSD Related Conditions</brief_title>
	<detailed_description />
	<criteria>Male female 18 65 year age Diagnosed current PTSD define ClinicianAdministered PTSD Scale DSM5 ( CAPS5 ) , For patient qualify Index trauma ( ) result PTSD occur military service , military contractor , Department Homeland Security law enforcement Willing able withdraw refrain specific therapy ( ask PI ) Use medically acceptable form contraception ( female ) Signed informed consent Significant traumatic brain injury Severe depression Bipolar psychotic disorder Increase risk suicide Significant clinical ( cardiac , systemic infection , drug/alcohol abuse ) laboratory abnormality ( include positivity Hep B , Hep C , HIV ) Unable washout specific medication ( ask PI ) History violent behavior within past 2 year , unrelated work duty History drug alcohol abuse within past 6 month Positive illegal substance test Known hypersensitivity cyclobenzaprine Others : seizure disorder , uncontrolled sleep apnea , BMI &gt; 40 Participation investigational study past 30 day In process litigate compensation psychiatric disorder Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Military-related PTSD related condition</keyword>
</DOC>